Spyre Therapeutics, Inc.
SYRE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $45,247 | $0 | $0 | $0 |
| Gross Profit | -$45,247 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $45,247 | $40,145 | $41,623 | $50,482 |
| G&A Expenses | $11,641 | $11,790 | $11,944 | $10,771 |
| SG&A Expenses | $11,641 | $11,790 | $11,944 | $10,771 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$45,247 | -$10,000 | $0 | $0 |
| Operating Expenses | $11,641 | $41,935 | $53,567 | $61,253 |
| Operating Income | -$56,888 | -$41,935 | -$53,567 | -$61,253 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $45,705 | $5,218 | $8,779 | $4,958 |
| Pre-Tax Income | -$11,183 | -$36,717 | -$44,788 | -$56,295 |
| Tax Expense | $0 | $0 | -$15 | $1 |
| Net Income | -$11,183 | -$36,717 | -$44,773 | -$56,296 |
| % Margin | – | – | – | – |
| EPS | -0.15 | -0.6 | -0.13 | -0.15 |
| % Growth | 75% | -361.5% | 13.3% | – |
| EPS Diluted | -0.15 | -0.6 | -0.13 | -0.15 |
| Weighted Avg Shares Out | 74,926 | 60,697 | 60,266 | 47,028 |
| Weighted Avg Shares Out Dil | 60,414 | 60,697 | 60,266 | 47,028 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,379 | $5,874 | $6,493 | $5,776 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$11,183 | -$51,935 | -$53,567 | -$61,253 |
| % Margin | – | – | – | – |